Products

The new BD MAX™ is the first fully-automated benchtop  molecular system for both CE-IVD and user-defined protocols allowing to run multiple specimen types and assays simultaneously.

IMAGINE the possibilities...

The BD MAX™ platform is an open system which enables laboratories to program and automate user-defined thermocycling and PCR-analysis protocols. Laboratories can use user-defined assays and other commercial assays in addition to those developed by BD.

Unitized Reagent Strips: an important asset for more efficient quality management.

All the reagents necessary for cell lysis, nucleic acid extraction, amplification and detection are contained in unitized reagent strips: pipette tips, lytic enzymes, extraction reagents, magnetic beads, wash buffers, master mix, probes, primers and internal control.

• Unitized reagent strips for ease of use
• Contains all reagents
• Room-temperature storage
• Individual 2D barcodes guarantee traceability of reagents

• Each chamber fits on an individually controlled heater, which allows different amplification protocols in the same cartridge.
• Rapid thermal cycling.

 To receive more information, please contact BD at: BDMAX@europe.bd.com

EXPLORE the possibilities...

Break - Snap - Load - Start run

With up to 24 results in less than 3 hours, BD MAX™ easily integrates into any routine laboratory workflow delivering the results your infection control team needs. Only 4 easy steps to perform Only 1.5 minutes of hands-on time

BD MAX™ Cdiff Assay: this diagnostic test is intended to rapidly, and accurately identify patients with clostridium difficile Infection(CDI) enabling appropriate treatment and infection control measures to be implemented quickly, helping to improve patient outcomes. The assay is designed to detect the toxin B gene (tcdB), the gene present in toxigenic C. difficile.

As the rate of C. diff infections continues to increase in hospitals and healthcare facilities worldwide, rapid, molecular testing for detection of toxigenic C.diff can help expedite appropriate treatment, reduce length of stay, and improve patient outcomes. ^1,2
 

Add - Snap - Load - Start run

With up to 24 results in < 3 hours, BD MAX™ Cdiff can be easily integrated into your routine laboratory workflow. Easy steps, only 1.5 minutes of hands-on time per sample

BD MAX™ StaphSR Assay delivers accurate and timely detection of MRSA & SA and is a key contributor to health intervention programs to prevent surgical site infections (SSIs) in healthcare settings. The StaphSR Assay with eXTended Detection Technology accurately identifies MRSA strains with the novel mecC cassette and new MREJ types and also the mecA dropouts that can cause MRSA false positives.

Simple & Efficient Workflow with less than 1 minute of hands-on time per specimen and results in about 2 hours. StaphSR testing can be combined with other HAI assays (MRSA, Cdiff and CRE RUO) and IVD assays from different syndromes (Enteric Bacterial).

User-defined protocols cannot be performed in the same run as IVD/CE assays.

1. Aberra et al., Medscape: Clostridium Difficile Colitis Epidemiology 2012; http://emedicine.medscape.com/article/186458-overview,
2. Catanzaro et al., American Journal of Infection Control (AJIC); Real-time polymerase chain reaction testing for Clostridium difficile reduces isolation time and improves patient management in a small community hospital (January 2012)

 To receive more information, please contact BD at: BDMAX@europe.bd.com

The Answer You Need Today From a Single Test Result

Assay Features

• Performance comparable to the "gold standard" cytotoxicity assay
• Real-time PCR results in <2 hours for toxigenic C. difficile
• Specific detection of the tcdB gene found only in toxigenic C. difficile
• One single method that can replace current C. difficile testing

Clinical Advantages

• Rapid, sensitive and specific results for patients suspected of having C. difficile infection (CDI)
• Earlier accurate diagnosis enables appropriate treatment of infected patients and can help avoid empiric treatment and unnecessary exposure to antibiotics in negative patients
• Facilitates targeted infection control practices to prevent transmission and infection.

Assay Features:

• Rapid, simultaneous detection and differentiation of MRSA and SA direct from positive blood culture bottles, wounds and nasal specimens.  

• Results in less than 2 hours vs. 2-3 days required for traditional microbiology culture methods
• Simple user-friendly workflow
• Aids in the differentiation of MRSA/SA and potential contaminants such as coagulase negative Staphylococcus.

Clinical Advantages:

• Rapid identification and treatment of BSIs has been proven to reduce healthcare costs and improve patient outcomes
• Promotes faster, better antibiotic selection to prevent the emergence of vancomycin resistant organisms
• Facilitates earlier isolation of patients infected with MRSA to prevent further transmission and infection

The BACTEC™ FX blood culturing instruments used with patented resin-containing media have shown higher rates of organism recovery, allowing for proper diagnosis and treatment of bloodstream infections

The BD Phoenix™ Automated Microbiology System , with its unique technology for susceptibility testing, provides high accuracy combined with rapid time to result. Because MRSA, VRE and Extended Spectrum beta-lactamase (ESBL) are the most important resistance markers linked to HAIs, the performance of the laboratory’s ID-AST system to detect these mechanisms is critical.